lumbar spinal stensis cervical spondylotic myelopathy
Conditions
Interventions
Bisphosphonate group as control group. This group is given Alendronate Sodium Hydrate (0.9mg/4week) from immediately after operation to 24 month after operation.
Daily PTH group. This group is given T
Sponsors
Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1: patient who undergone the spinal surgery for LSS or CSM 2: patieit who fullfil the criteria of osteoporosis 3: patient whose age is more than 60 y.o. 4: patient who agree with this study, with well understanding
Exclusion criteria
Exclusion criteria: 1: patient who already taken the medicine for porosis before surgery. 2: patient who is tought to be hard to continue the study. 3: patient with OPLL or OYL 4: patient who is as an outpatieents of dentist 5: patient who has high risk of osteosarcoma 6: patient with hypercalcemia 7: patient with malignant tumor 8: patient with metabolic bone disease 9: patient who is taking digitalis. 10: patient with allergy for bisphosphonat or teriparatide 11: patient whose renal dysfunction 12: pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recovery rate of JOA scores at 24 year postoperatively | — |
Secondary
| Measure | Time frame |
|---|---|
| JOACMEQ JOABPEQ SF-36 VAS bone union rate screw loosenisng rate BMD new fracture rate | — |
Countries
Japan
Contacts
Public ContactAkinobu Suzuki
Osaka City University Orthopedics
Outcome results
None listed